| Cystic Fibrosis
Kalydeco vs Symdeko
Side-by-side clinical, coverage, and cost comparison for cystic fibrosis.Deep comparison between: Kalydeco vs Symdeko with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSymdeko has a higher rate of injection site reactions vs Kalydeco based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Symdeko but not Kalydeco, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kalydeco
Symdeko
At A Glance
Oral
Every 12 hours
CFTR potentiator
Oral
Twice daily
CFTR corrector/potentiator
Indications
- Cystic Fibrosis
- Cystic Fibrosis
Dosing
Cystic Fibrosis Weight-based dosing every 12 hours with fat-containing food: oral granules from 5.8 mg (1 to <2 months, >=3 kg) up to 75 mg (6 months to <6 years, >=14 kg); 150 mg tablet for patients >=6 years; dose reduced to once daily for moderate hepatic impairment or concomitant moderate CYP3A inhibitors (>=6 months), and to twice weekly for strong CYP3A inhibitors (>=6 months).
Cystic Fibrosis Adults and patients >=12 years, or patients 6 to <12 years weighing >=30 kg: tezacaftor 100 mg/ivacaftor 150 mg in the morning and ivacaftor 150 mg in the evening, approximately 12 hours apart, with fat-containing food; patients 6 to <12 years weighing <30 kg: tezacaftor 50 mg/ivacaftor 75 mg in the morning and ivacaftor 75 mg in the evening, approximately 12 hours apart, with fat-containing food. Dose adjustment required for moderate or severe hepatic impairment and for co-administration with CYP3A inhibitors.
Contraindications
—
—
Adverse Reactions
Most common (>=8%) Headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, dizziness
Serious Abdominal pain, increased hepatic enzymes, hypoglycemia, transaminase elevations
Postmarketing Anaphylaxis, intracranial hypertension, anxiety, depression, suicidal ideation and behavior, insomnia
Most common (>=3%) headache, nausea, sinus congestion, dizziness
Serious transaminase elevations, hypersensitivity reactions including anaphylaxis, intracranial hypertension, neuropsychiatric events including suicidal thoughts and behaviors, cataracts, distal intestinal obstruction syndrome
Postmarketing anaphylaxis, rash, intracranial hypertension, anxiety, depression, suicidal ideation and behavior, insomnia
Pharmacology
Ivacaftor is a CFTR potentiator that facilitates increased chloride transport by potentiating the channel open probability (gating) of CFTR protein located at the epithelial cell surface; clinical benefit requires at least one ivacaftor-responsive CFTR mutation identified by clinical and/or in vitro assay data.
Tezacaftor/ivacaftor is a CFTR corrector/potentiator combination; tezacaftor facilitates cellular processing and trafficking of mutant CFTR protein (including F508del-CFTR) to the cell surface, while ivacaftor potentiates CFTR channel-open probability, together increasing the quantity and function of CFTR at the cell surface and resulting in increased chloride transport.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kalydeco
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Symdeko
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Kalydeco
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (1/8)
Symdeko
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Kalydeco
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Symdeko
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Cystic Fibrosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Cystic Fibrosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KalydecoView full Kalydeco profile
SymdekoView full Symdeko profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.